

## Response to: 'JAK inhibitors as promising agents for refractory Takayasu arteritis' by Watanabe

We thank Watanabe for his interest in our case report showing that tofacitinib, a janus kinase (JAK) inhibitor, successfully induced a remission of Takayasu arteritis (TAK) complicated by ulcerative colitis (UC)<sup>1</sup> and for providing some meaningful comments to supplement our discussion.<sup>2</sup> Watanabe wonders if JAK inhibitors can be effective in TAK patients without UC. In addition, he is concerned that types of JAK inhibitors may affect the efficiency in treating TAK. We agree that the issues should be evaluated in a large-scale case series and clinical study. According to a limited number of case reports, JAK inhibitors were effective in TAK regardless of coexisting UC and types of JAK inhibitors. Sato *et al* reported a similar case of TAK with UC successfully treated with tofacitinib (JAK1/JAK3 inhibitor).<sup>3</sup> On the other hand, Régnier *et al* reported that ruxolitinib or baricitinib (JAK1/JAK2 inhibitors) clinically improved TAK without UC in three patients.<sup>4</sup> They also demonstrated that the improvement was along with decrease of Th1/Th17-related cytokines and correction of effector/regulatory T-cell imbalance. However, as suggested by Watanabe, JAK inhibitors could modulate innate immunity composed of macrophages and natural killer cells in TAK.

For the management of refractory TAK, EULAR recommends considering tumour necrosis factor (TNF) inhibitor or tocilizumab,<sup>5</sup> although the evidence for TNF inhibitor depends on only open-label studies,<sup>6</sup> and a randomised controlled trial of tocilizumab failed to achieve its primary endpoint.<sup>7</sup> Tocilizumab rapidly normalises IL-6-driven serum inflammatory markers despite sustained vessel inflammation.<sup>1 8</sup> It can be confusing when the disease activity of TAK is correctly assessed. Thus, additional treatment options with clear evidence have been desired for TAK. To conclude, we believe that further studies should be conducted in refractory TAK for evaluating the efficacy and safety of JAK inhibitors as a promising agent.

Shun Tanimura , Hiroyuki Nakamura, Tetsuya Horita 

Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan

**Correspondence to** Dr Tetsuya Horita, Internal Medicine, Tomakomai City Hospital, Tomakomai 053-8567, Japan; thorita@med.hokudai.ac.jp

**Contributors** ST and HN wrote the manuscript. TH contributed to the discussion and edited the manuscript. All authors read and approved the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Tanimura S, Nakamura H, Horita T. *Ann Rheum Dis* 2022;**81**:e68.

Received 20 April 2020  
Accepted 23 April 2020  
Published Online First 7 May 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-217577>

*Ann Rheum Dis* 2022;**81**:e68. doi:10.1136/annrheumdis-2020-217680

### ORCID iDs

Shun Tanimura <http://orcid.org/0000-0002-9640-2527>

Tetsuya Horita <http://orcid.org/0000-0003-2332-3841>

### REFERENCES

- 1 Kuwabara S, Tanimura S, Matsumoto S, *et al*. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. *Ann Rheum Dis* 2020;**79**:1125–6.
- 2 Watanabe R. Jak inhibitors as promising agents for refractory Takayasu arteritis. *Ann Rheum Dis* 2022;**81**:e67.
- 3 Sato S, Matsumoto H, Temmoku J, *et al*. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. *Rheumatology* 2019;**17**. doi:10.1093/rheumatology/kez580
- 4 Régnier P, Le Joncour A, Maciejewski-Duval A, *et al*. Targeting JAK/STAT pathway in Takayasu's arteritis. *Ann Rheum Dis* 2020;**79**:951–9.
- 5 Hellmich B, Agueda A, Monti S, *et al*. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* 2020;**79**:19–30.
- 6 Águeda AF, Monti S, Luqmani RA, *et al*. Management of Takayasu arteritis: a systematic literature review Informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. *RMD Open* 2019;**5**:e001020.
- 7 Nakaoka Y, Isobe M, Takei S, *et al*. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). *Ann Rheum Dis* 2018;**77**:348–54.
- 8 Tanimura S, Kato M, Abe N, *et al*. Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab. *Immunol Med* 2018;**41**:39–42.